Research Article

Department of Breast Oncology, Sun Yat-sen University Cancer Center; State Key Laboratory of Oncology in South China; Collaborative Innovation Center of Cancer Medicine; Address: 651 East Dongfeng Road, Guangzhou, PR China

^‡Authors contributed equally

Lu Yang^‡

^‡Authors contributed equally

Search for more papers by this author

Weidong Wei^‡

^‡Authors contributed equally

Search for more papers by this author

Ning Lyu

Department of Minimally Invasive Interventional Radiology, Sun Yat-sen University Cancer Center; State Key Laboratory of Oncology in South China; Collaborative Innovation Center of Cancer Medicine; Address: 651 East Dongfeng Road, Guangzhou, PR China

Search for more papers by this author

Yutian Zou

Search for more papers by this author

Guanfeng Gao

Search for more papers by this author

Xueqi Ou

Search for more papers by this author

Xiaoming Xie

**Authors for correspondence: Tel.: +86 208 734 3806; Fax: +86 208 734 3805;

E-mail Address: xiexm@sysucc.org.cn

Search for more papers by this author

Hailin Tang

*Authors for correspondence: Tel. and Fax: +86 208 734 3805;

E-mail Address: tanghl@sysucc.org.cn

Search for more papers by this author

Published Online:24 Jul 2019https://doi.org/10.2217/epi-2019-0093

View article

Abstract

Aim: To investigate the role of circRNAs in triple-negative breast cancer (TNBC) and the underlying mechanisms. Materials & methods: We performed circRNA microarrays to explore the expression profiles of TNBC cell lines. Experiments in vitro and in vivo were conducted to explore the effects of circPLK1 on tumor proliferation and metastasis as well as the interaction between circPLK1, miR-296-5p and PLK1 in TNBC. Results & conclusion: CircPLK1 was significantly upregulated in TNBC and associated with poor survivals. CircPLK1 knockdown inhibited cell growth and invasion in vitro as well as tumor occurrence and metastasis in vivo. CircPLK1-miR-296-5p-PLK1 axis regulates tumor progression by ceRNA mechanism in TNBC, indicating that circPLK1 may serve as a prognostic factor and novel therapeutic target for TNBC.

Keywords:

Papers of special note have been highlighted as: • of interest; •• of considerable interest

References

1. Perou CM, Sorlie T, Eisen MB et al. Molecular portraits of human breast tumours. Nature 406(6797), 747–752 (2000). • Revealed molecular subtypes and portraits of breast cancer.
Medline CASGoogle Scholar
2. Carey L, Winer E, Viale G, Cameron D, Gianni L. Triple-negative breast cancer: disease entity or title of convenience? Nat. Rev. Clin. Oncol. 7(12), 683–692 (2010).
MedlineGoogle Scholar
3. De Laurentiis M, Cianniello D, Caputo R et al. Treatment of triple negative breast cancer (TNBC): current options and future perspectives. Cancer Treat. Rev. 36(Suppl. 3), S80–S86 (2010).
MedlineGoogle Scholar
4. Chen LL. The biogenesis and emerging roles of circular RNAs. Nat. Rev. Mol. Cell Biol. 17(4), 205–211 (2016). •• Systemically reviews the biogenesis and roles of circular RNAs.
Medline CASGoogle Scholar
5. Jeck WR, Sharpless NE. Detecting and characterizing circular RNAs. Nat. Biotechnol. 32(5), 453–461 (2014).
Medline CASGoogle Scholar
6. Tay Y, Rinn J, Pandolfi PP. The multilayered complexity of ceRNA crosstalk and competition. Nature 505(7483), 344–352 (2014).
Medline CASGoogle Scholar
7. Salmena L, Poliseno L, Tay Y, Kats L, Pandolfi PP. A ceRNA hypothesis: the Rosetta Stone of a hidden RNA language? Cell 146(3), 353–358 (2011). •• The ceRNA hypothesis is proposed at the first time.
Medline CASGoogle Scholar
8. Karreth FA, Pandolfi PP. ceRNA cross-talk in cancer: when ce-bling rivalries go awry. Cancer Discov. 3(10), 1113–1121 (2013).
Medline CASGoogle Scholar
9. Memczak S, Jens M, Elefsinioti A et al. Circular RNAs are a large class of animal RNAs with regulatory potency. Nature 495(7441), 333–338 (2013).
Medline CASGoogle Scholar
10. Hansen TB, Jensen TI, Clausen BH et al. Natural RNA circles function as efficient microRNA sponges. Nature 495(7441), 384–388 (2013). • Reveals that circRNAs may function as efficient miRNA sponges.
Medline CASGoogle Scholar
11. Hsiao KY, Lin YC, Gupta SK et al. Noncoding effects of circular RNA CCDC66 promote colon cancer growth and metastasis. Cancer Research 77(9), 2339–2350 (2017).
Medline CASGoogle Scholar
12. Panda AC, Grammatikakis I, Kim KM et al. Identification of senescence-associated circular RNAs (SAC-RNAs) reveals senescence suppressor CircPVT1. Nucleic Acids Res. 45(7), 4021–4035 (2017).
Medline CASGoogle Scholar
13. Neve RM, Chin K, Fridlyand J et al. A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell 10(6), 515–527 (2006).
Medline CASGoogle Scholar
14. Kristensen LS, Hansen TB, Veno MT, Kjems J. Circular RNAs in cancer: opportunities and challenges in the field. Oncogene 37(5), 555–565 (2018). • Thoroughly reviews the past and the future of circular RNAs in cancer.
Medline CASGoogle Scholar
15. Lasda E, Parker R. Circular RNAs: diversity of form and function. RNA 20(12), 1829–1842 (2014).
Medline CASGoogle Scholar
16. Chen J, Li Y, Zheng Q et al. Circular RNA profile identifies circPVT1 as a proliferative factor and prognostic marker in gastric cancer. Cancer Lett. 388, 208–219 (2017).
Medline CASGoogle Scholar
17. Savi F, Forno I, Faversani A et al. miR-296/Scribble axis is deregulated in human breast cancer and miR-296 restoration reduces tumour growth in vivo. Clin. Sci. (Lond.) 127(4), 233–242 (2014).
Medline CASGoogle Scholar
18. Dinami R, Buemi V, Sestito R et al. Epigenetic silencing of miR-296 and miR-512 ensures hTERT dependent apoptosis protection and telomere maintenance in basal-type breast cancer cells. Oncotarget 8(56), 95674–95691 (2017).
MedlineGoogle Scholar
19. Li H, Li J, Shi B, Chen F. MicroRNA296 targets AKT2 in pancreatic cancer and functions as a potential tumor suppressor. Mol. Med. Rep. 16(1), 466–472 (2017).
Medline CASGoogle Scholar
20. Shi DM, Li LX, Bian XY et al. miR-296-5p suppresses EMT of hepatocellular carcinoma via attenuating NRG1/ERBB2/ERBB3 signaling. J. Exp. Clin. Cancer Res. 37(1), 294 (2018).
Medline CASGoogle Scholar
21. Zhang Z, Zhong X, Xiao Y, Chen C. MicroRNA-296 inhibits colorectal cancer cell growth and enhances apoptosis by targeting ARRB1-mediated AKT activation. Oncol. Rep. 41(1), 619–629 (2019).
Medline CASGoogle Scholar
22. Sutterlin C, Lin CY, Feng Y, Ferris DK, Erikson RL, Malhotra V. Polo-like kinase is required for the fragmentation of pericentriolar Golgi stacks during mitosis. Proc. Natl Acad. Sci. USA 98(16), 9128–9132 (2001).
Medline CASGoogle Scholar
23. Degenhardt Y, Lampkin T. Targeting polo-like kinase in cancer therapy. Clin. Cancer Res. 16(2), 384–389 (2010).
Medline CASGoogle Scholar
24. Johnson EF, Stewart KD, Woods KW, Giranda VL, Luo Y. Pharmacological and functional comparison of the polo-like kinase family: insight into inhibitor and substrate specificity. Biochemistry 46(33), 9551–9563 (2007).
Medline CASGoogle Scholar
25. Lansing TJ, Mcconnell RT, Duckett DR et al. In vitro biological activity of a novel small-molecule inhibitor of polo-like kinase 1. Mol. Cancer Ther. 6(2), 450–459 (2007).
Medline CASGoogle Scholar
26. Lens SM, Voest EE, Medema RH. Shared and separate functions of polo-like kinases and aurora kinases in cancer. Nat. Rev. Cancer 10(12), 825–841 (2010).
Medline CASGoogle Scholar
27. Takaki T, Trenz K, Costanzo V, Petronczki M. Polo-like kinase 1 reaches beyond mitosis–cytokinesis, DNA damage response, and development. Curr. Opin. Cell Biol. 20(6), 650–660 (2008).
Medline CASGoogle Scholar
28. Wolf G, Hildenbrand R, Schwar C et al. Polo-like kinase: a novel marker of proliferation: correlation with estrogen-receptor expression in human breast cancer. Pathol. Res. Pract. 196(11), 753–759 (2000).
Medline CASGoogle Scholar
29. Hu K, Law JH, Fotovati A, Dunn SE. Small interfering RNA library screen identified polo-like kinase-1 (PLK1) as a potential therapeutic target for breast cancer that uniquely eliminates tumor-initiating cells. Breast Cancer Res. 14(1), R22 (2012).
Medline CASGoogle Scholar
30. Takahashi T, Sano B, Nagata T et al. Polo-like kinase 1 (PLK1) is overexpressed in primary colorectal cancers. Cancer Sci. 94(2), 148–152 (2003).
Medline CASGoogle Scholar
31. Wolf G, Elez R, Doermer A et al. Prognostic significance of polo-like kinase (PLK) expression in non-small cell lung cancer. Oncogene 14(5), 543–549 (1997).
Medline CASGoogle Scholar
32. Tokumitsu Y, Mori M, Tanaka S, Akazawa K, Nakano S, Niho Y. Prognostic significance of polo-like kinase expression in esophageal carcinoma. Int. J. Oncol. 15(4), 687–692 (1999).
Medline CASGoogle Scholar
33. Takai N, Miyazaki T, Fujisawa K, Nasu K, Hamanaka R, Miyakawa I. Polo-like kinase (PLK) expression in endometrial carcinoma. Cancer Lett. 169(1), 41–49 (2001).
Medline CASGoogle Scholar
34. Takai N, Miyazaki T, Fujisawa K, Nasu K, Hamanaka R, Miyakawa I. Expression of polo-like kinase in ovarian cancer is associated with histological grade and clinical stage. Cancer Lett. 164(1), 41–49 (2001).
Medline CASGoogle Scholar
35. Gray PJ Jr., Bearss DJ, Han H et al. Identification of human polo-like kinase 1 as a potential therapeutic target in pancreatic cancer. Mol. Cancer Ther. 3(5), 641–646 (2004).
Medline CASGoogle Scholar
36. Cogswell JP, Brown CE, Bisi JE, Neill SD. Dominant-negative polo-like kinase 1 induces mitotic catastrophe independent of cdc25C function. Cell Growth Differ. 11(12), 615–623 (2000).
Medline CASGoogle Scholar
37. Gumireddy K, Reddy MV, Cosenza SC et al. ON01910, a non-ATP-competitive small molecule inhibitor of Plk1, is a potent anticancer agent. Cancer Cell 7(3), 275–286 (2005).
Medline CASGoogle Scholar
38. Liu X, Lei M, Erikson RL. Normal cells, but not cancer cells, survive severe Plk1 depletion. Mol. Cell Biol. 26(6), 2093–2108 (2006).
MedlineGoogle Scholar
39. Nogawa M, Yuasa T, Kimura S et al. Intravesical administration of small interfering RNA targeting PLK-1 successfully prevents the growth of bladder cancer. J. Clin. Invest. 115(4), 978–985 (2005).
Medline CASGoogle Scholar
40. Spankuch-Schmitt B, Wolf G, Solbach C et al. Downregulation of human polo-like kinase activity by antisense oligonucleotides induces growth inhibition in cancer cells. Oncogene 21(20), 3162–3171 (2002).
Medline CASGoogle Scholar
41. Xie S, Xie B, Lee MY, Dai W. Regulation of cell cycle checkpoints by polo-like kinases. Oncogene 24(2), 277–286 (2005).
MedlineGoogle Scholar
42. Xu C, Li S, Chen T et al. miR-296-5p suppresses cell viability by directly targeting PLK1 in non-small cell lung cancer. Oncol. Rep. 35(1), 497–503 (2016).
Medline CASGoogle Scholar

Vol. 11, No. 10

Supplemental Materials

Metrics

Downloaded 337 times

History

Received 11 July 2016

Accepted 6 July 2016

Published online 24 July 2019

Published in print August 2019

Information

Keywords

Supplementary data

To view the supplementary data that accompany this paper please visit the journal website at: www.futuremedicine.com/doi/full/10.2217/epi-2019-0093

Financial & competing interests disclosure

This work was supported by funds from the National Natural Science Foundation of China (81772961, H Tang; 81872152, X Xie; 81702620, L Yang). The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

No writing assistance was utilized in the production of this manuscript.

Ethical conduct of research

This study was approved by the Ethics Committee of Sun Yat-Sen University Cancer Center Health Authority and was performed according to the ethical standards of the Declaration of Helsinki. All animal studies were approved and performed according to the guidelines of the Institutional Animal Care and Use Committee of Sun Yat-Sen University Cancer Center.

PDF download

CircPLK1 sponges miR-296-5p to facilitate triple-negative breast cancer progression

Abstract

References